Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Myo-inositol (MI), successfully used in polycystic ovary syndrome (PCOS), was administered with α-LA to exploit its action of favouring the passage of other molecules through biological barriers, and also considering its anti-inflammatory effect. METHODS: PCOS patients, according to the Rotterdam ESHRE-ASRM criteria, with anovulation and infertility > 1 year, were included in this open and prospective study. The preliminary phase was aimed at determining a set of MI-resistant PCOS patients. This treatment involved 2 g MI, taken twice per day by oral route, for three months. The Homeostasis Model Assessment (HOMA) index and MI plasma levels were measured. In the main phase, previously selected MI-resistant patients received the same daily amount of MI plus 50 mg α-LA twice a day, for a further three months. Ovulation was assessed using ultrasound examination on days 12, 14 and 20 of the cycle. The HOMA index, lipid, hormone and MI plasma levels were detected at baseline and at the end of this phase. RESULTS: Thirty-seven anovulatory PCOS subjects were included in the study. Following MI treatment, 23 of the 37 women (62%) ovulated, while 14 (38%) were resistant and did not ovulate. In the latter group, MI plasma levels did not increase. These MI-resistant patients underwent treatment in the main phase of the study, receiving MI and α-LA. After this combined treatment, 12 (86%) of them ovulated. Their MI plasma levels were found to be significantly higher than at baseline; also, a hormone and lipid profile improvement was recorded. CONCLUSION: The combination of MI with α-LA allowed us to obtain significant progress in the treatment of PCOS MI-resistant patients. Therefore, this new formulation was able to re-establish ovulation, greatly increasing the chances of desired pregnancy. TRIAL REGISTRATION: Clinical trial registration number: NCT03422289 ( ClinicalTrials.gov registry).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
González, F. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.003 · Cited by 515
Tremellen, K., & Pearce, K. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.04.016 · Cited by 359 · cited 3×
“to this pathology, such as hyperandrogenism and IR Inflammation in women with PCOS (which appears to be established by multiple factors among which, as reported before, intestinal dysbiosis) [28].”
BackgroundEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Self-citationSchneider, S. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.03.012 · Cited by 118
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106
Self-citationInsulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · cited 1×
“[20] the period of treatment with myoinositol lasted six months; however, it did not reduce the number of MI-resistant patients, obtaining a value (35%) that was even slightly lower than that found by our team after three months.”
ResultGonzález, F. (2015) · Seminars in Reproductive Medicine · doi:10.1055/s-0035-1554918 · Cited by 60
Wang, X., Ai, T., Meng, X. L., Zhou, J., & Mao, X. Y. (2014) · Journal of Dairy Science · doi:10.3168/jds.2013-7461 · Cited by 38
Cited by
Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020583 · Cited by 445
“(Treatment-Related) Liraglutide Phase III/2018 [140] Exp: 0.6 mg liraglutide, SC pen injector, QD for one week, step up to 1.2 mg, SC pen injector, QD for one week, to 1.8 mg, SC pen injector, QD for one week, 2.4 mg, SC pen injector, QD for one week, to 3 mg, SC pen injector, QD final dose P: 0.6 mg placebo liragluti…”
BackgroundInfluentialInositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
Self-citationInositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Self-citationKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Self-citation
Metadata
- Authors
- Montanino Oliva, M., Buonomo, G., Calcagno, M., & Unfer, V.
- Venue
- Journal of Ovarian Research
- Published
- 2018-05-10
- Volume
- 11
- Issue
- 1
- Pages
- 38-38
- ISSN
- 1757-2215 (ISSN-L)
- OpenAlex
- W2804088205
- Cited by
- 62
- References
- 8
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. https://app.cochat.ai/papers/10.1186/s13048-018-0411-2
- The paper
- Montanino Oliva, M., Buonomo, G., Calcagno, M., & Unfer, V. (2018). Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. Journal of Ovarian Research. https://doi.org/10.1186/s13048-018-0411-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.